French Company Genticel Talks About Patents it Won in the US
French biotechnology company Genticel, which leads the market in therapeutic vaccines has recently won a flurry of patent awards in the US. The company has recently enriched its Intellectual Property estate by issuing patents in different places, and Genticel spokesperson came out in public to disclose more about their patent wins.
Since the beginning of 2014 Genticel’s patent lawyers have been working wonders. The company has been given five major patents in important territories that will help in consolidating Genticel’s products and the product pipeline. The French company that develops therapeutic vaccines aims to establish its market hold with the help of these new patents and increase its share of the emerging and mature pharmaceutical markets more than what it already possesses.
Genticel aims for long lasting IP protection
The company is looking at its patent wins as long lasting IP protection and hopes that these patents will help it secure its place in the markets. The French pharma company holds an exclusive license given by the Institute
No pun intended but Genticel seems to have a winning formula.
Pasteur which relates to five patent families. These five patents protect the recombinant adenylate cyclase vector technology (CyaA) that Genticel uses in its products. The domains of this exclusive license that Genticel holds cover important areas in immune-therapy and immune-therapy applications. These domains also include prophylactic vaccines for humans as well as for veterinary uses.
As Genticel’s patent lawyers explain, the company has license over five patent families and two of these have already been granted patents. These patents cover ” CyaA-based technology (in particular the new VAXICLASE platform), CyaA-based vaccines (including pipeline products) and therapeutic uses”. The patent lawyers also discussed the company’s strategy which aims at assuring long term protection of Genticel’s product candidates, and all the technology platforms the company will be using in various markets.
Genticel’s patents in detail
Genticel has been awarded the following patents : US 8628779, IN 258906 and KR 10-1382250, granted in the USA, India, and South Korea, respectively. The first was awarded on January 14th, the second was given to the company on the 14th of February and the last one was on April 1st. The patents, as explained by the patent attorneys representing Genticel―claim and relate to using “a recombinant protein carrying human papillomavirus (HPV) epitopes inserted in an adenylate cyclase protein or fragments thereof”. The granted claims protect Genticel’s candidate therapeutic vaccine ProCervix, and also contain claims that cover other HPV therapeutic vaccines with multiple antigens such as the ones used in Genticel’s follow-on candidate product, Multivalent HPV.
Genticel is bringing home the bacon.
Genticel is getting it done
In addition to these, the patent US 8637039 which was granted on January 28th covers a HPV treatment comprising proprietary methods that are currently used in the ongoing Phase II efficacy trial with the lead candidate medicine put out by Genticle – ProCervix.
The last patent JP 5496669 which was granted to the company in Japan on the 14th of March protects a composition for “eliciting a specific cyto-toxic T cell response, comprising a lympho-ablative compound and a molecule (containing an antigenic sequence) that targets professional antigen-presenting cells.”
The patents and their specifications are particularly appropriate for the administration of ProCervix – Genticel’s leading drug. They are also useful for related immunotherapeutics which can be used in combination with immunosuppressive drugs for the treatment of advanced disease indications such as cervical carcinoma, HPV-associated anal disease and disease of the oropharyngeal tract caused by the virus.
Genticel would have accomplished all of this years ago if they were not taxed at such a high rate. In fact, the world would have a cure for cancer if governments did not tax pharmaceutical companies so much according to some financial wise men.
